Biology of Blood and Marrow Transplantation
Volume 15, Issue 11 , Pages 1415-1421 , November 2009

Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation

  • Joseph Pidala

      Affiliations

    • Departments of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute, Tampa, Florida
    • Department of Oncological Sciences, University of South Florida, Tampa, Florida
    • Corresponding Author InformationCorrespondence and reprint requests: Joseph Pidala, MD, Moffitt Cancer Center, 12902 Magnolia Drive, MCC-GME, Tampa, FL 33612-9416.
    • ,
  • Claudio Anasetti

      Affiliations

    • Departments of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute, Tampa, Florida
    • Department of Oncological Sciences, University of South Florida, Tampa, Florida
    • ,
  • Mohamed A. Kharfan-Dabaja

      Affiliations

    • Departments of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute, Tampa, Florida
    • Department of Oncological Sciences, University of South Florida, Tampa, Florida
    • ,
  • Corey Cutler

      Affiliations

    • Department of Blood and Marrow Transplantation, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Andy Sheldon

      Affiliations

    • TreeAge Software, Inc, Williamstown, MA
    • ,
  • Benjamin Djulbegovic

      Affiliations

    • Departments of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute, Tampa, Florida
    • Department of Oncological Sciences, University of South Florida, Tampa, Florida

Received 10 April 2009 ,Accepted 7 July 2009.

References 

  1. Bensinger WI, Longin K, Appelbaum F, et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol. 1994;87:825–831
  2. Chao NJ, Schriber JR, Grimes K, et al. Granulocyte colony-stimulating factor “mobilized” peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood. 1993;81:2031–2035
  3. de Fabritiis P, Iori AP, Mengarelli A, et al. CD34+ cell mobilization for allogeneic progenitor cell transplantation: efficacy of a short course of G-CSF. Transfusion. 2001;41:190–195
  4. Siena S, Bregni M, Brando B, et al. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1989;74:1905–1914
  5. Socinski MA, Cannistra SA, Elias A, et al. Granulocyte-macrophage colony-stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet. 1988;1:1194–1198
  6. Gratwohl A, Baldomero H, Horisberger B, et al. Current trends in hematopoietic stem cell transplantation in Europe. Blood. 2002;100:2374–2386
  7. Bahceci E, Read EJ, Leitman S, et al. CD34+ cell dose predicts relapse and survival after T-cell–depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies. Br J Haematol. 2000;108:408–414
  8. Bittencourt H, Rocha V, Chevret S, et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood. 2002;99:2726–2733
  9. Cao TM, Shizuru JA, Wong RM, et al. Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Blood. 2005;105:2300–2306
  10. Hassan HT, Stockschlader M, Schleimer B, et al. Comparison of the content and subpopulations of CD3- and CD34-positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors. Transpl Immunol. 1996;4:319–323
  11. Larghero J, Rocha V, Porcher R, et al. Association of bone marrow natural killer cell dose with neutrophil recovery and chronic graft-versus-host disease after HLA-identical sibling bone marrow transplants. Br J Haematol. 2007;138:101–109
  12. Martin PJ, Rowley SD, Anasetti C, et al. A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients. Blood. 1999;94:2192–2199
  13. Nakamura R, Bahceci E, Read EJ, et al. Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell–depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back. Br J Haematol. 2001;115:95–104
  14. Panse JP, Heimfeld S, Guthrie KA, et al. Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning. Br J Haematol. 2005;128:659–667
  15. Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood. 2006;108:1291–1297
  16. Theilgaard-Monch K, Raaschou-Jensen K, Andersen H, et al. Single leukapheresis products collected from healthy donors after the administration of granulocyte colony-stimulating factor contain ten-fold higher numbers of long-term reconstituting hematopoietic progenitor cells than conventional bone marrow allografts. Bone Marrow Transplant. 1999;23:243–249
  17. Urbano-Ispizua A, Rozman C, Pimentel P, et al. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood. 2001;97:383–387
  18. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344:175–181
  19. Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol. 2000;18:537–546
  20. Cornelissen JJ, van der Holt B, Petersen EJ, et al. A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies. Exp Hematol. 2003;31:855–864
  21. Couban S, Simpson DR, Barnett MJ, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood. 2002;100:1525–1531
  22. Heldal D, Tjonnfjord G, Brinch L, et al. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant. 2000;25:1129–1136
  23. Mahmoud H, Fahmy O, Kamel A, et al. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 1999;24:355–358
  24. Morton J, Hutchins C, Durrant S. Granulocyte colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF–mobilized peripheral blood stem cells. Blood. 2001;98:3186–3191
  25. Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet. 2000;355:1231–1237
  26. Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood. 2002;100:761–767
  27. Vigorito AC, Azevedo WM, Marques JF, et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant. 1998;22:1145–1151
  28. Vigorito AC, Marques JF, Aranha FJ, et al. A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of hematologic malignancies: an update. Haematologica. 2001;86:665–666
  29. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23:5074–5087
  30. Dawson B, Trapp RG. Basic & Clinical Biostatistics. New York: Lange Medical Books/McGraw-Hill; 2004;311-326
  31. Hunink MGM. Decision Making in Health and Medicine: Integrating Evidence and Values. Cambridge, UK: Cambridge University Press; 2001;305-363
  32. Stewart BL, Storer B, Storek J, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004;104:3501–3506
  33. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care. 2005;43:736–749
  34. Lee SJ, Kuntz KM, Horowitz MM, et al. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. Ann Intern Med. 1997;127:1080–1088
  35. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579–585
  36. Sung L, Buckstein R, Doyle JJ, et al. Treatment options for patients with acute myeloid leukemia with a matched sibling donor: a decision analysis. Cancer. 2003;97:592–600
  37. Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002;100:1201–1207
  38. Horowitz MM. Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol. 2000;37:30–42
  39. Kahl C, Leisenring W, Deeg HJ, et al. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol. 2005;130:747–751
  40. Lucarelli G, Clift RA, Galimberti M, et al. Bone marrow transplantation in adult thalassemic patients. Blood. 1999;93:1164–1167
  41. Sevilla J, Fernandez-Plaza S, Diaz MA, et al. Hematopoietic transplantation for bone marrow failure syndromes and thalassemia. Bone Marrow Transplant. 2005;35(Suppl 1):S17–S21

 Financial disclosure: See Acknowledgments on page 1420.

PII: S1083-8791(09)00324-3

doi: 10.1016/j.bbmt.2009.07.009

Biology of Blood and Marrow Transplantation
Volume 15, Issue 11 , Pages 1415-1421 , November 2009

Article Tools

* Image Usage & Resolution